Healthcare

• FDA alignment confirmed on regulatory pathway for a New Drug Application

• EBIT rose 18.7% to A$582.9 million in the half-year result

According to the announcement, Actinogen's pivotal XanaMIA Phase 2b/3 trial, which is evaluating Xanamem in 247 patients with mild to moderate Alzheimer's disease across Australia and the United States, remained on track during FY26. The company said the trial had received three positive recommendations …

• FY26Revenuereached $261.7 million, up 22.9% year-on-year (28.4% in constant currency), while NPAT rose 24.1% to $144.7 million (32.5% in constant currency), with the Company beating market forecasts despite currency headwinds.

• The Company has elected to initially draw down only 50% of the committed A$34 million, considered sufficient to fund all currently planned activities including completion of the ACTION3 Phase 3 trial of DMX-200 in FSGS and the Phase 2 trial of DMX-652 in …

• PROIBS® is a European-certified medical device, not a supplement, targeting abdominal pain, bloating, and unsettled bowel movements; the US digestive and gut health supplement market is valued at US$4.16 billion (Mordor Intelligence), with Immuron targeting a specific segment of this market.

Starpharma released itsAnnual Reportand full-year financial results for the year ended 30 June 2026 on 26 August 2026. FY26 revenue increased 145% to $12.0 million, up from $4.9 million in FY25, driven primarily by an $8.3 million upfront payment received from the Genentech licence …